novel treatments

Research in Review

Adding Targeted Therapy Improves CAR-T Response Rates in CLL

06/15/2017

JCP Editors

Researchers report significantly improved response rates in patients with chronic lymphocytic leukemia (CLL) treated with concurrent targeted therapy and chimeric antigen receptor T-cell (CAR-T)...

...

06/15/2017

Journal of Clinical Pathways

Research in Review

Brain Metastases Resistant to Targeted Therapy Due to Gene Overexpression

06/14/2017

JCP Editors

A novel mechanism responsible for brain metastasis resistance to targeted therapy has been identified, which may help guide treatment strategies, according to a study published in Science Translational Medicine...

A...

06/14/2017

Journal of Clinical Pathways

Research in Review

PARP Inhibitors Crucial to the Future of Ovarian Cancer Treatment

06/12/2017

JCP Editors

The treatment landscape in the coming decade for ovarian cancers will likely feature poly ADP ribose polymerase (PARP) inhibitors in combination with other treatments, according to reports from a recent...

The...

06/12/2017

Journal of Clinical Pathways

Research in Review

Standard of Care Shift in ALK-Positive Lung Cancer

06/12/2017

JCP Editors

A second-generation inhibitor delays anaplastic lymphoma kinase (ALK)-positive lung cancer growth for a median of 15 months longer and causes fewer adverse events than the current standard of care, according to a new...

A...

06/12/2017

Journal of Clinical Pathways

Research in Review

Immunotherapy Improves Standard of Care for Multiple Myeloma

06/08/2017

JCP Editors

Adding a targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma is a safe and efficacious alternative to autologous stem cell transplantation (ASCT) with KRd,...

Adding...

06/08/2017

Journal of Clinical Pathways

Research in Review

Panel Highlights Uses of Genomic Testing for Breast Cancer

06/07/2017

JCP Editors

A panel of breast cancer experts offered an education session on the value of standard and genomic testing for breast cancer at the 2017 American Society of Clinical Oncology Annual Meeting (June 2-6, 2017; Chicago,...

A...

06/07/2017

Journal of Clinical Pathways

Research in Review

Metastatic Hormone-Na√Øve Prostate Cancer Effectively Treated With Combination Therapy

06/07/2017

JCP Editors

Groundbreaking results of a trial have shown that the combination of a new drug with androgen deprivation therapy (ADT) significantly improves overall survival (OS) and radiographic progression-free survival (PFS) in...

...

06/07/2017

Journal of Clinical Pathways

Research in Review

Imaging Needed to Monitor Melanoma Brain Metastases During PD-1 Therapy

06/03/2017

JCP Editors

Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at...

...

06/03/2017

Journal of Clinical Pathways

Research in Review

Triple Combination Active in High-Risk B-Cell Malignancies

05/24/2017

JCP Editors

A combination of 3 pathway inhibitors is well tolerated with activity observed in heavily pre-treated and high-risk B-cell malignancies, according to research that will be presented at the ASCO Annual Meeting (June...

A...

05/24/2017

Journal of Clinical Pathways

Research in Review

Risk-Adapted Therapy Reduces Treatment Toxicity for Patients With Hodgkin Lymphoma

05/19/2017

JCP Editors

A combined chemotherapy approach may eliminate the toxic effects of radiation therapy in children and young adults with Hodgkin lymphoma, according to early results of a study that will be presented at the 2017 ASCO...

A...

05/19/2017

Journal of Clinical Pathways